Abstract
The AMJ is a peer-reviewed, triannual health journal published by Anuradhapura Clinical Society (ACS).The Journal strives to be a forum for all health professionals to publish original research and review articles in their area of expertise. The AMJ publishes articles in clinical medicine, public health and health promotion. Our priority is given to manuscripts on health related issues which affects the communities living in rural tropical communities. Established as a journal in 2006 as a publication parallel to ACS annual scientific sessions, the journal was relaunched as a proper journal in 2013. Anuradhapura Medical Journal is a member of COPE and is included on DOAJ.
Highlights
If Sri Lanka is to meet its own target of eliminating human rabies deaths by 2016, the Ministry of Health and the public must support the PHVS in a strong, sustained effort to meet this goal
In addition to the target of global elimination of leprosy as a public health problem by 2020, the NTD Roadmap targets a reduction of the global rate of new cases with grade-2 disabilities per 1 million population, by at least 35% by the end of 2015, compared with the baseline of 2010 [2]
The vast majority of cases of leishmaniasis in Sri Lanka are of the cutaneous type, it has been clearly established that they are caused by Leishmania donovani (which causes the much deadlier visceral leishmaniasis (VL) in the Indian sub-continent), a few cases with visceral and muco-cutaneous manifestations have been reported [9]
Summary
Sri Lanka is very fortunate in that unlike many other developing countries, we have to combat only six of the 17 NTDs: dengue, rabies, leprosy, leishmaniasis, lymphatic filariasis and the soil-transmitted helminthiases. These figures suggest that Sri Lanka is well on its way to reaching the target relating to mortality reduction, but that morbidity reduction (as measured in terms of the incidence rate) is going to be much more difficult, because an effective, commercially available dengue vaccine appears to be some years away.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
